Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading volume and capital flow, with a slight increase in share price on November 27, 2025, despite net outflows from major and retail investors [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, an increase of 5.89% year-on-year [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43% [3]. Market Position - Meihao Medical's total market capitalization is 11.997 billion yuan, which is higher than the industry average of 11.026 billion yuan, ranking 25th out of 124 in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 43.22, which is lower than the industry average of 56.75, ranking 48th out of 124 [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd out of 124 [3]. Investor Sentiment - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating positive sentiment among analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan [4].
股票行情快报：美好医疗（301363）11月27日主力资金净卖出104.15万元